Skip to main content
SpringerLink
Log in
Book cover

Lung Disease Associated with Rheumatoid Arthritis pp 59–77Cite as

Therapeutic Strategy for Airway Disease in Rheumatoid Arthritis

  • Chapter
  • First Online:

Abstract

Despite the high prevalence of airway disease in patients with rheumatoid arthritis (RA), its significance in the clinical practice of RA has not been well discussed. The significance of airway disease can be summarized as follows. (1) It can predispose patients to infectious diseases such as pneumonia and nontuberculous mycobacterial disease. (2) It may cause progressive impairment of lung function, leading to obstructive malfunction and ultimate respiratory failure. (3) In some cases, airway inflammation can result in the destruction of bronchioles and surrounding lung parenchyma, leading to the formation of cysts mimicking a honeycomb lung. In this chapter, we discuss these problems by presenting typical clinical cases and consider the pathogenesis of those processes and finally show the treatment strategy for each problem, based on the limited available literature and the author’s opinion. The most important point is that airway disease is an extra-articular manifestation of RA, and if left untreated, it may exacerbate the patients’ medical condition and cause deterioration with serious consequences. These problems should be addressed from the viewpoint of how to control the inflammation caused by the excessive immune response of RA.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Takayanagi N. Biological agents and respiratory infections: causative mechanisms and practice management. Respir Investig. 2015;53:185–200.

    Article  PubMed  Google Scholar 

  2. Mori S, Tokuda H, Sakai F, Johkoh T, Mimori A, Nishimoto N, et al. Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan. Mod Rheumatol. 2012;22:727–37.

    Article  CAS  PubMed  Google Scholar 

  3. Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, et al. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2013;65:1243–50.

    Article  Google Scholar 

  4. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628–34.

    Article  CAS  PubMed  Google Scholar 

  5. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–93.

    Article  PubMed  Google Scholar 

  6. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403–12.

    Article  CAS  PubMed  Google Scholar 

  7. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124–31.

    Article  CAS  Google Scholar 

  8. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70:1914–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lieberman-Maran L, Orzano IM, Passero MA, Lally EV. Bronchiectasis in rheumatoid arthritis: report of four cases and a review of the literature—implications for management with biologic response modifiers. Semin Arthritis Rheum. 2006;35:379–87.

    Article  PubMed  Google Scholar 

  10. Swinson DR, Symmons D, Suresh U, Jones M, Booth J. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol. 1997;36:689–91.

    Article  CAS  PubMed  Google Scholar 

  11. Tsuchiya Y, Takayanagi N, Sugita Y, Miyahara Y, Tokunaga D, Kawabata Y, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37:1411–7.

    Article  CAS  PubMed  Google Scholar 

  12. Puéchal X, Génin E, Bienvenu T, Le Jeunne C, Dusser DJ. Poor survival in rheumatoid arthritis associated with bronchiectasis: a family-based cohort study. PLoS One. 2014;9:e110066.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Siemieniuk R, Meade M, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:519–28.

    Article  PubMed  Google Scholar 

  14. Tokuda H, Harigai M, Watanabe A, Hideto Kameda H, Tomono K, Takayanagi N, et al. Consensus statements for medical practice: biological agents and lung disease. Abridged English translation by the Japanese Respiratory Society. Respir Investig. 2017;55:229–51.

    Article  PubMed  Google Scholar 

  15. Gotfried MH, Grossman RF. Short-course fluoroquinolones in acute exacerbations of chronic bronchitis. Expert Rev Resp Med. 2010;4:661–72.

    Article  CAS  Google Scholar 

  16. Kawasumi H, Gono T, Tanaka E, Kaneko H, Kawaguchi Y, Yamanaka H. Clinical characteristics and cytokine profiles of organizing pneumonia in patients with rheumatoid arthritis treated with or without biologics. J Rheumatol. 2016;43:738–44.

    Article  PubMed  Google Scholar 

  17. Banno S, Nobata H, Kitagawa W, et al. Safety and efficacy of biological therapy with rheumatoid arthritis associated pulmonary disease as interstitial lung disease or airway disease. Mod Rheumatol. 2015;163(25 Suppl):W66–5. http://www.ryumachi-jp.com/publication/pdf/mr_supple_all_2015.pdf. Accessed 30 Jan 2017.

    Google Scholar 

  18. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial diseases and anti-tumor necrosis factor therapy in USA. Ann Rheum Dis. 2013;72:37–42.

    Article  CAS  PubMed  Google Scholar 

  19. Tokuda H. Broncho-bronchial disorders in patients with rheumatoid arthritis [in Japanese]. Rinsho Hoshasen. 2015;60:1085–96.

    Google Scholar 

  20. Komazaki Y, Miyazaki Y, Fujie T, Sakashita H, Tsuchiya K, Tamaoka M, et al. Serodiagnosis of Mycobacterium avium complex pulmonary disease in rheumatoid arthritis. Respiration. 2014;87:129–35.

    Article  CAS  PubMed  Google Scholar 

  21. Mori S, Koga Y, Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:164–73.

    Article  PubMed  Google Scholar 

  22. Wilsher M, Voight L, Milne D, Teh M, Good N, Kolbe J, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med. 2012;106:1441–6.

    Article  PubMed  Google Scholar 

  23. Devouassoux G, Cottin V, Lioté H, Marchand E, Frachon I, Schuller A, et al. Characterization of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J. 2009;33:1053–61.

    Article  CAS  PubMed  Google Scholar 

  24. Hayakawa H, Sato A, Chida K, Toyoshima M, Chida K, Iwata M. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med. 1996;154:1531–6.

    Article  CAS  PubMed  Google Scholar 

  25. Tsang WT, Ho PL, Lam WK, Ip MS, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158:723–7.

    Article  CAS  PubMed  Google Scholar 

  26. Saag KG, Furst DE, Barnes PJ. Major side effects of inhaled glucocorticoids. UpToDate. https://www.uptodate.com/contents/major-side-effects-of-inhaled-glucocorticoids. Accessed 30 Jan 2017.

  27. Blaser MJ. Missing microbes. New York: Henry Holt & Company; 2014. p. 164.

    Google Scholar 

  28. Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270:583–8.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Walsh S, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax. 2014;69:216–22.

    Article  PubMed  Google Scholar 

  30. Solomon J, Chung J, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016;47:588–96.

    Article  PubMed  Google Scholar 

  31. Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2017;56(3):344–50. pii: kew391.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Tokyo Yamate Medical Center, Japan Community Health Care Organization (JCHO), Tokyo, Japan

    Hitoshi Tokuda M.D., Ph.D.

Authors
  1. Hitoshi Tokuda M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hitoshi Tokuda M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Takahisa Gono

  2. Department of Respiratory Medicine, JCHO Tokyo Yamate Medical Center, Tokyo, Japan

    Hitoshi Tokuda

  3. Department of Diagnostic Radiology, Saitama International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan

    Fumikazu Sakai

  4. Department of Pathology , Japanese Red Cross Medical Center, Tokyo, Japan

    Tamiko Takemura

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tokuda, H. (2018). Therapeutic Strategy for Airway Disease in Rheumatoid Arthritis. In: Gono, T., Tokuda, H., Sakai, F., Takemura, T. (eds) Lung Disease Associated with Rheumatoid Arthritis. Springer, Singapore. https://doi.org/10.1007/978-981-10-6750-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-6750-1_5

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-6749-5

  • Online ISBN: 978-981-10-6750-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation